CFTR Modulators Counteract F508del CFTR Functional Defects in a Pancreatic Epithelial Model of Cystic Fibrosis
Open Access
Abstract
Cystic fibrosis is a multisystem disorder caused by mutations in the CFTR gene that lead to impaired ion and fluid transport across secretory epithelia. Although the therapeutic impact of CFTR modulators has been extensively studied in airway epithelia, their efficacy in extra-pulmonary tissues, such as the pancreas, has been less explored. This study evaluated the effects of the CFTR modulators, VX770 (ivacaftor), VX661 (tezacaftor), and VX445 (elexacaftor), administered either individually or in combination, on CFPAC-1 cells, a pancreatic ductal epithelial cell line derived from a cystic fibrosis patient harboring the F508del CFTR mutation. The cells were cultured and differentiated onto porous supports, and a panel of functional parameters was assessed. These included transepithelial electrical conductance, fluid reabsorption, apical surface fluid pH, protein concentration, and microviscosity, the latter analyzed with multiple particle tracking. To simulate a pro-inflammatory micro-environment, the cells were preconditioned with lipopolysaccharide (LPS). Treatment with VX661 and VX445 resulted in significant improvement in epithelial function, with the triple combination producing the most pronounced rescue. Pro-inflammatory stimulation by LPS increased the production of cytokine IL6, IL-8, and IL-1β, as well as the protein content of the apical surface fluid. Despite the LPS pro-inflammatory stimulus, CFTR modulators preserved or slightly enhanced their efficacy in restoring CFTR-mediated ion and fluid transport. However, they did not reduce cytokine expression under pro-inflammatory conditions. Collectively, these findings show that CFTR modulators can restore critical aspects of cystic fibrosis pancreatic epithelial physiology in vitro, even under pro-inflammatory stress, supporting their potential relevance beyond the airway disease.Keywords
This publication has 105 references indexed in Scilit:
- Mucus, mucins, and cystic fibrosisPediatric Pulmonology, 2019
- Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL‐1 signaling pathwayPediatric Pulmonology, 2019
- Pancreatic pathophysiology in cystic fibrosisThe Journal of Pathology, 2015
- Mucins: A biologically relevant glycan barrier in mucosal protectionBiochimica et Biophysica Acta (BBA) - General Subjects, 2015
- Suppression of cytokine production in lipopolysaccharide-stimulated mouse macrophages by novel cationic glucosamine derivative involves down-regulation of NF-κB and MAPK expressionsBioorganic & Medicinal Chemistry, 2008
- Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screeningHuman Mutation, 2002
- Cystic Fibrosis of the Pancreas: Involvement of MUC6 Mucin in Obstruction of Pancreatic DuctsMolecular Medicine, 1997
- Angiotensin II Receptor Type I-Regulated Anion Secretion in Cystic Fibrosis Pancreatic Duct CellsThe Journal of Membrane Biology, 1997
- Defective ATP‐dependent mucin secretion by cystic fibrosis pancreatic epithelial cellsFEBS Letters, 1996
- Direct double antibody sandwich immunoassay of mucin M1 epitopes in human mucus secreting pancreatic cell linesClinica Chimica Acta, 1995